Midecamycin

DB13456

small molecule experimental

Deskripsi

Midecamycin is a naturally occurring 16-membered macrolideA33072 that fits under the category of acetoxy-substituted macrolide antibiotics. In this molecule, an acetoxy group is substituted on the position 9 of the 16-member ring and on position 4 of the terminal sugar.A33075 Until 2017, midecamycin was still under the list of approved antimicrobial active pharmaceutical ingredients by Health Canada.L2791

Struktur Molekul 2D

Berat 813.979
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The half-life of midecamycin is longer than the first macrolide antibiotics.[A33081] after intravenous administration, the half-life reported is of 54 minutes.[A33082]
Volume Distribusi The reported apparent volume of distribution of midecamycin is 7.7 L/kg.[A33082]
Klirens (Clearance) Midecamycin presentas a low renal clearance value.[A33081]

Absorpsi

Midecamycin is rapidly and almost completely absorbed when orally administered.A33075 It is mainly absorbed in the alkaline intestinal environment. This rapid absorption is due to its liposoluble property which allows for good penetration in the tissues, especially bronchial secretion, prostatic tissue, middle ear exudates and bone tissue. The tissue/serum ratio concentration is greater than 1 which indicates that this product does not stay long in the plasma. After oral administration of 600 mg of midecamycin, the peak serum concentration is 0.8 mg/L and it is attained 1 hour after oral administration. This concentration dereased significantly after 4-6 hours.A33081

Metabolisme

Midecamycin undergoes extensive biotransformation in the liver and its metabolites are characterized by presenting little to no antimicrobial activity. The main metabolite is formed by a 14-hydroxylation and it can be also detected in urine.A33081

Rute Eliminasi

The major route of elimination of midecamycin is is the liver, followed by a low significance of renal elimination. Urinary concentrations accounts for about 3.3% of the administered dose after 6 hours.A33081

Interaksi Obat

397 Data
Eliglustat The metabolism of Eliglustat can be decreased when combined with Midecamycin.
Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Midecamycin.
Alfentanil The serum concentration of Alfentanil can be increased when it is combined with Midecamycin.
Buspirone The metabolism of Buspirone can be decreased when combined with Midecamycin.
Carbamazepine The metabolism of Carbamazepine can be decreased when combined with Midecamycin.
Cisapride The serum concentration of Cisapride can be increased when it is combined with Midecamycin.
Disopyramide Midecamycin may increase the QTc-prolonging activities of Disopyramide.
Estazolam The serum concentration of Estazolam can be increased when it is combined with Midecamycin.
Quinine The serum concentration of Quinine can be increased when it is combined with Midecamycin.
Quinidine The serum concentration of Quinidine can be increased when it is combined with Midecamycin.
Repaglinide The serum concentration of Repaglinide can be increased when it is combined with Midecamycin.
Sirolimus The metabolism of Sirolimus can be decreased when combined with Midecamycin.
Temsirolimus The metabolism of Temsirolimus can be decreased when combined with Midecamycin.
Terfenadine The serum concentration of Terfenadine can be increased when it is combined with Midecamycin.
Triazolam The serum concentration of Triazolam can be increased when it is combined with Midecamycin.
Cilostazol The metabolism of Cilostazol can be decreased when combined with Midecamycin.
Colchicine The metabolism of Colchicine can be decreased when combined with Midecamycin.
Iloperidone The metabolism of Iloperidone can be decreased when combined with Midecamycin.
Retapamulin The metabolism of Retapamulin can be decreased when combined with Midecamycin.
Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Midecamycin.
Vardenafil The metabolism of Vardenafil can be decreased when combined with Midecamycin.
Eszopiclone The metabolism of Eszopiclone can be decreased when combined with Midecamycin.
Zopiclone The metabolism of Zopiclone can be decreased when combined with Midecamycin.
Lovastatin The metabolism of Lovastatin can be decreased when combined with Midecamycin.
Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Midecamycin.
Alprazolam The serum concentration of Alprazolam can be increased when it is combined with Midecamycin.
Warfarin The serum concentration of Warfarin can be increased when it is combined with Midecamycin.
Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Midecamycin.
(R)-warfarin The serum concentration of (R)-warfarin can be increased when it is combined with Midecamycin.
R,S-Warfarin alcohol The serum concentration of R,S-Warfarin alcohol can be increased when it is combined with Midecamycin.
S,R-Warfarin alcohol The serum concentration of S,R-Warfarin alcohol can be increased when it is combined with Midecamycin.
(S)-Warfarin The serum concentration of (S)-Warfarin can be increased when it is combined with Midecamycin.
Midazolam The serum concentration of Midazolam can be increased when it is combined with Midecamycin.
Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Midecamycin.
Telaprevir The serum concentration of Telaprevir can be increased when it is combined with Midecamycin.
Picosulfuric acid The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Midecamycin.
Vintafolide The serum concentration of Vintafolide can be increased when it is combined with Midecamycin.
Vincamine The serum concentration of Vincamine can be increased when it is combined with Midecamycin.
Acetyldigitoxin The serum concentration of Acetyldigitoxin can be increased when it is combined with Midecamycin.
Deslanoside The serum concentration of Deslanoside can be increased when it is combined with Midecamycin.
Ouabain The serum concentration of Ouabain can be increased when it is combined with Midecamycin.
Oleandrin The serum concentration of Oleandrin can be increased when it is combined with Midecamycin.
Cymarin The serum concentration of Cymarin can be increased when it is combined with Midecamycin.
Proscillaridin The serum concentration of Proscillaridin can be increased when it is combined with Midecamycin.
Metildigoxin The serum concentration of Metildigoxin can be increased when it is combined with Midecamycin.
Lanatoside C The serum concentration of Lanatoside C can be increased when it is combined with Midecamycin.
Gitoformate The serum concentration of Gitoformate can be increased when it is combined with Midecamycin.
Acetyldigoxin The serum concentration of Acetyldigoxin can be increased when it is combined with Midecamycin.
Peruvoside The serum concentration of Peruvoside can be increased when it is combined with Midecamycin.
Cyclosporine The metabolism of Cyclosporine can be decreased when combined with Midecamycin.
Dicoumarol The serum concentration of Dicoumarol can be increased when it is combined with Midecamycin.
Phenindione The serum concentration of Phenindione can be increased when it is combined with Midecamycin.
Coumarin The serum concentration of Coumarin can be increased when it is combined with Midecamycin.
Tioclomarol The serum concentration of Tioclomarol can be increased when it is combined with Midecamycin.
Ethyl biscoumacetate The serum concentration of Ethyl biscoumacetate can be increased when it is combined with Midecamycin.
Diphenadione The serum concentration of Diphenadione can be increased when it is combined with Midecamycin.
4-hydroxycoumarin The serum concentration of 4-hydroxycoumarin can be increased when it is combined with Midecamycin.
Fluindione The serum concentration of Fluindione can be increased when it is combined with Midecamycin.
Clorindione The serum concentration of Clorindione can be increased when it is combined with Midecamycin.
Oxtriphylline The metabolism of Oxtriphylline can be decreased when combined with Midecamycin.
Doxofylline The metabolism of Doxofylline can be decreased when combined with Midecamycin.
Bamifylline The metabolism of Bamifylline can be decreased when combined with Midecamycin.
Acefylline The metabolism of Acefylline can be decreased when combined with Midecamycin.
Bufylline The metabolism of Bufylline can be decreased when combined with Midecamycin.
Fenethylline The metabolism of Fenethylline can be decreased when combined with Midecamycin.
Proxyphylline The metabolism of Proxyphylline can be decreased when combined with Midecamycin.
Bromotheophylline The metabolism of Bromotheophylline can be decreased when combined with Midecamycin.
Pentoxifylline The metabolism of Pentoxifylline can be decreased when combined with Midecamycin.
8-azaguanine The metabolism of 8-azaguanine can be decreased when combined with Midecamycin.
7,9-Dimethylguanine The metabolism of 7,9-Dimethylguanine can be decreased when combined with Midecamycin.
Xanthine The metabolism of Xanthine can be decreased when combined with Midecamycin.
7-Deazaguanine The metabolism of 7-Deazaguanine can be decreased when combined with Midecamycin.
Guanine The metabolism of Guanine can be decreased when combined with Midecamycin.
9-Methylguanine The metabolism of 9-Methylguanine can be decreased when combined with Midecamycin.
Peldesine The metabolism of Peldesine can be decreased when combined with Midecamycin.
Hypoxanthine The metabolism of Hypoxanthine can be decreased when combined with Midecamycin.
9-Deazaguanine The metabolism of 9-Deazaguanine can be decreased when combined with Midecamycin.
Valomaciclovir The metabolism of Valomaciclovir can be decreased when combined with Midecamycin.
3-isobutyl-1-methyl-7H-xanthine The metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Midecamycin.
Uric acid The metabolism of Uric acid can be decreased when combined with Midecamycin.
6-O-benzylguanine The metabolism of 6-O-benzylguanine can be decreased when combined with Midecamycin.
Lisofylline The metabolism of Lisofylline can be decreased when combined with Midecamycin.
Lobucavir The metabolism of Lobucavir can be decreased when combined with Midecamycin.
Cafedrine The metabolism of Cafedrine can be decreased when combined with Midecamycin.
Theodrenaline The metabolism of Theodrenaline can be decreased when combined with Midecamycin.
Etamiphylline The metabolism of Etamiphylline can be decreased when combined with Midecamycin.
Pentifylline The metabolism of Pentifylline can be decreased when combined with Midecamycin.
Furafylline The metabolism of Furafylline can be decreased when combined with Midecamycin.
Theobromine The metabolism of Theobromine can be decreased when combined with Midecamycin.
Propentofylline The metabolism of Propentofylline can be decreased when combined with Midecamycin.
Caffeine The metabolism of Caffeine can be decreased when combined with Midecamycin.
8-chlorotheophylline The metabolism of 8-chlorotheophylline can be decreased when combined with Midecamycin.
Mercaptopurine The metabolism of Mercaptopurine can be decreased when combined with Midecamycin.
PCS-499 The metabolism of PCS-499 can be decreased when combined with Midecamycin.
Methylergometrine The serum concentration of Methylergometrine can be increased when it is combined with Midecamycin.
Lisuride The serum concentration of Lisuride can be increased when it is combined with Midecamycin.
Nicergoline The serum concentration of Nicergoline can be increased when it is combined with Midecamycin.
Ergoloid mesylate The serum concentration of Ergoloid mesylate can be increased when it is combined with Midecamycin.
Pergolide The serum concentration of Pergolide can be increased when it is combined with Midecamycin.
Ergometrine The serum concentration of Ergometrine can be increased when it is combined with Midecamycin.

Referensi & Sumber

Artikel (PubMed)
  • PMID: 11531981
    Schlegel L, Merad B, Rostane H, Broc V, Bouvet A: In vitro activity of midecamycin diacetate, a 16-membered macrolide, against Streptococcus pyogenes isolated in France, 1995-1999. Clin Microbiol Infect. 2001 Jul;7(7):362-6.
  • PMID: 6639001
    Neu HC: In vitro activity of midecamycin, a new macrolide antibiotic. Antimicrob Agents Chemother. 1983 Sep;24(3):443-4.
  • PMID: 2656049
    Periti P, Mazzei T, Mini E, Novelli A: Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part I). Clin Pharmacokinet. 1989 Apr;16(4):193-214. doi: 10.2165/00003088-198916040-00001.
  • PMID: 7154248
    Inoue A, Deguchi T: The pharmacokinetic studies on spiramycin and acetylspiramycin in rats. Jpn J Antibiot. 1982 Aug;35(8):1998-2004.
  • PMID: 6982352
    Yoshida T, Watanabe T, Shomura T, Someya S, Okamoto R, Ishihara S, Miyauchi K, Kazuno Y: Bacteriological evaluation of midecamycin acetate and its metabolites. Jpn J Antibiot. 1982 Jun;35(6):1462-74.
Textbook
  • Bycroft B. and Payne D. (2014). Dictionary of Antibiotic and Related Substances (2nd ed.). CRC Press.
  • Omura S. (2002). Macrolide antibiotics: Chemistry, Biology and Practice (2nd ed.). Academic Press.
  • Garbis H., Tonningen M. and Reuvers M. (2007). Drugs during Pregnancy and Lactation (2nd ed.). Academic Press.

Contoh Produk & Brand

Produk: 0 • International brands: 1
International Brands
  • Medemycin — Main Life Corporation

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul